Anna Walley
Family · Jackson, MSNPI 1528373586
Payments from drug & device makers
Across 669 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$5K
- GSK$3K
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$980
- Mallinckrodt Hospital Products Inc.$912
- Boehringer Ingelheim$838
- plus $5K from 31 others
What the payments were for
- Travel & lodging$3,04218%
- Food & beverage$14,05581%
- Education$2021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 39 | $4,695 |
| GSK | 185 | $3,174 |
| AstraZeneca | 55 | $1,434 |
| Jazz Pharmaceuticals Inc. | 39 | $980 |
| Mallinckrodt Hospital Products Inc. | 46 | $912 |
| Boehringer Ingelheim | 51 | $838 |
| Sanofi | 27 | $665 |
| Actelion Pharmaceuticals US, Inc. | 24 | $627 |
| ANI Pharmaceuticals, Inc. | 5 | $475 |
| Axsome Therapeutics, Inc. | 18 | $471 |
| Mylan Specialty L.p. | 18 | $323 |
| Regeneron Healthcare Solutions, Inc. | 13 | $309 |
| Insmed, Inc. | 13 | $266 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $250 |
| Johnson & Johnson | 14 | $205 |
| United Therapeutics Corporation | 8 | $177 |
| IBSA Pharma Inc. | 9 | $177 |
| Bayer | 13 | $170 |
| Verona Pharma, Inc. | 17 | $160 |
| Merck | 7 | $117 |
| Baxter Healthcare | 6 | $113 |
| Harmony Biosciences LLC | 5 | $107 |
| Genentech USA, Inc. | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 6 | $84 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $62 |
| Electromed, Inc. | 8 | $62 |
| Pfizer | 4 | $59 |
| Viatris Specialty LLC | 3 | $50 |
| Advanced Respiratory, Inc | 3 | $47 |
| Mayne Pharma Commercial LLC | 2 | $37 |
| Philips North America LLC | 2 | $32 |
| Eisai Inc. | 2 | $30 |
| Amgen | 2 | $29 |
| Pulmonx Corporation | 1 | $20 |
| Itamar Medical Inc | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,298 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 22 | $483,174 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 532 | $426,680 |
| Breo ElliptaFluticasone/Vilanterol | 119 | $60,524 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $53,792 |
| EliquisApixaban | 66 | $52,632 |
| XareltoRivaroxaban | 46 | $49,258 |
| SymbicortBudesonide/Formoterol Fumarate | 146 | $46,455 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $35,805 |
| Spiriva HandihalerTiotropium Bromide | 47 | $27,168 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $26,817 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $17,335 |
| Spiriva RespimatTiotropium Bromide | 16 | $13,037 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $12,235 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 251 | $9,202 |
| BreynaBudesonide/Formoterol Fumarate | 44 | $8,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $3,174 | $540,343762 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $627 | $483,17422 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,434 | $100,247218 claims |
| PfizerEliquis | $59 | $52,63266 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat | $838 | $52,08868 claims |
| Johnson & JohnsonXarelto | $205 | $49,25846 claims |
| MerckDulera | $117 | $4,42113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Jackson
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Leondrea CollinsJackson$28K
- Elizabeth WilliamsJackson$18K
- Teresa SpencerJackson$16K
- Catherine PageJackson$14K
- Mollie DotyJackson$12K
- Marty GebhartJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.